Authors: HYLEK EM HEIMAN H SKATES SJ SHEEHAN MA SINGER DE

Citation: Em. Hylek et al., ACETAMINOPHEN AND OTHER RISK-FACTORS FOR EXCESSIVE WARFARIN ANTICOAGULATION, JAMA, the journal of the American Medical Association, 279(9), 1998, pp. 657-662

Authors: MCCALMON RT TARDIF GN SHEEHAN MA FITTING K KORTZ W KAM I

Citation: Rt. Mccalmon et al., IGM ANTIBODIES IN RENAL-TRANSPLANTATION, Clinical transplantation, 11(6), 1997, pp. 558-564

Authors: HYLEK EM SKATES SJ HEIMAN H SHEEHAN MA SINGER DE

Citation: Em. Hylek et al., RISK-FACTORS FOR EXCESSIVE ANTICOAGULATION AMONG OUTPATIENTS TAKING WARFARIN, Circulation, 96(8), 1997, pp. 2103-2103

Authors: HYLEK EM SKATES SJ SHEEHAN MA SINGER DE

Citation: Em. Hylek et al., AN ANALYSIS OF THE LOWEST EFFECTIVE INTENSITY OF PROPHYLACTIC ANTICOAGULATION FOR PATIENTS WITH NONRHEUMATIC ATRIAL-FIBRILLATION, The New England journal of medicine, 335(8), 1996, pp. 540-546

Authors: KISTLER JP SINGER DE MILLENSON MM BAUER KA GRESS DR BARZEGAR S HUGHES RA SHEEHAN MA MARAVENTANO SW OERTEL LB ROSNER B ROSENBERG RD

Citation: Jp. Kistler et al., EFFECT OF LOW-INTENSITY WARFARIN ANTICOAGULATION ON LEVEL OF ACTIVITYOF THE HEMOSTATIC SYSTEM IN PATIENTS WITH ATRIAL-FIBRILLATION, Stroke, 24(9), 1993, pp. 1360-1365